Login
Register
Submit a Paper
Propose a Special lssue
Open Access
ARTICLE
What is the optimal duration of androgen deprivation therapy in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/ml?
1
Vancouver Island Centre, BC Cancer Agency, University of British Columbia, British Columbia, Canada
2
Vancouver Centre, BC Cancer Agency, University of British Columbia, British Columbia, Canada
3
Fraser Valley Centre, BC Cancer Agency, University of British Columbia, British Columbia, Canada
Address correspondence to Dr. Eric Berthelet, Radiation
Therapy Program, BC Cancer Agency, Vancouver Island
Centre, 2410 Lee Avenue, Victoria, BC V8R 6V5 Canada
Canadian Journal of Urology 2007, 14(4), 3621-3627.
Download PDFAbstract
Purpose: To evaluate the optimal duration of androgen deprivation therapy (ADT) in patients with prostate cancer treated with external beam radiotherapy (EBRT), who present with PSA levels >20 ng/mL.Materials and methods: A total of 307 patients presenting with a PSA >20 ng/ml were treated with EBRT and ADT. The cohort was divided into four groups according to the duration of ADT: Group 1 received <6 months (n=71), group 2 received 6-12 months (n=80), group 3 received 12-24 months (n=72), and group 4 received >24 months (n=84) of ADT. The endpoints analyzed were biochemical control (bNED), overall survival (OS) and cause-specific survival (CSS). Statistical analysis was conducted using Kaplan-Meier estimates and Cox regression models.
Results: Compared to patients who received <6 months of ADT, patients treated with 12-24 months or >24 months of ADT experienced significantly improved bNED (p=0.01 and p<0.0001, respectively). Cause-specific survival with ADT durations 12-24 and >24 months were significantly higher compared to <6 months (p<0.007 and 0.024, respectively). Overall survival with ADT durations >24 months was also significantly higher compared to <6 months (p=0.0025).
Conclusions: The present analysis supports the hypothesis that longer durations of ADT improves bNED, CSS and OS in patients presenting with a PSA >20 ng/ml.
Keywords
prostate cancer, androgen deprivation therapy, prostate specific antigen, biochemical outcome, prostate radiotherapy
Cite This Article
APA Style
Berthelet, E., Pickles, T., Truong, P.T., Liu, M., Pai, H.H. et al. (2007). What is the optimal duration of androgen deprivation therapy in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/ml?. Canadian Journal of Urology, 14(4), 3621–3627.
Vancouver Style
Berthelet E, Pickles T, Truong PT, Liu M, Pai HH, Kwan WB, et al. What is the optimal duration of androgen deprivation therapy in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/ml?. Can J Urology. 2007;14(4):3621–3627.
IEEE Style
E. Berthelet et al., “What is the optimal duration of androgen deprivation therapy in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/ml?,” Can. J. Urology, vol. 14, no. 4, pp. 3621–3627, 2007.
Copyright © 2007 The Author(s). Published by Tech Science Press.This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Downloads
Citation Tools
